Aquarius Life Science
Aquarius is a high-growth startup biotech that will develop, protect, and license the technology to sequence the epigenome of single cells.
Aquarius is a biotechnology company developing a DNA methylation assay for industry, academic, and government researchers. The long-term goal is to validate the assay for use as an in vitro diagnostic for patients with cancer and other pathologies. The field of epigenetics has been described by analysts as the next paradigm shift in biology. The epigenetics research tool sector is estimated to be worth between 50 and 100 million dollars.